Cannabis stocks have taken off around the world. And with the medicinal cannabis industry growing, and legalisation around the corner, Australian cannabis stocks are starting to get noticed.
Updated May 2020. ASX data updated daily.
Here’s the largest list of cannabis companies listed on the ASX in 2020:
The 2020 Aussie Pot Stock List
Althea Group – AGH
Althea is currently one of the largest cannabis stocks in Australia. One of the reasons they’re the largest is because they’ve successful be granted licences to Cultivate, Manufacture, and Export cannabis products.
They’re a market leader in the industry, having already sold their first medicinal cannabis products to patients in May 2018. Althea plans to continue their growth through strategic partnerships – aiming to become the leading and most trusted medicinal cannabis brand in Australia.
They’ve redesigned their website and continue to make significant progress across Australia, Canada, and the UK. As well, they signed a supply and distribution agreement for one of the largest pharmaceutical wholesalers in Germany with a 25% market share.
Auscann Group Holdings – AC8
AusCann is one of the few companies that continues to pave the way in the Australian cannabis landscape. They’ve been at the forefront of the industry from the get go, bringing together experts and operations from all channels of the cannabis supply chain.
Through their valuable licences, they already provide some of their proven cannabinoid medicines through their partners existing 24,000 strong patient base.
AusCann are also one of the few listed ASX stocks that are conducting clinical trials to strengthen the evidence for medicinal cannabis.
Auscann continues to stride forward in the medicinal cannabis market across Australia. The compnay is now ready to commence its first clinical evaluation at an independent clinical site. Their hard-shell capsule products are also now available for prescribing by authorised doctors in Australia.
BOD Australia – BDA
BOD currently develops and sells a number of health care and wellbeing products in Australia and New Zealand. They work with a range of plant based extracts, including cannabis and hemp.
BOD plans to continue to build up a wholly integrated cannabis business, with agreements already in place with Swiss and Singaporean companies.
Eventually, the company wishes to utilise its already expansive distribution network in Australia (over 1,000 retail outlets) to supply its pharmaceutical grade cannabis extracts.
BOD are at the forefront of medicinal cannabis. As of early 2020, they have hundreds of prescriptions for their CBD medicines, and have recently secured agreements to distribute in the UK as well.
Botanix Australia – BOT
Botonix plan to improves the lives of thousands of patients suffering from mild to serious skin diseases including acne, dermatitis, and psoriasis, through the use of cannabidiol.
They’re currently conducting a number of clinical trials which are at varying stages of progression (you can see latest updates on their website).
Setting them apart one step further is their plan to deliver the medicines via a proprietary drug delivery system called Permatex.
Botanix continues to conduct its clinical trials throughout 2020. As of writing, they have five (5) products in the pipeline – all available in detailed description on their website.
Cann Global – CGB
Cann Global has a 100% shareholding of Medical Cannabis Ltd and Medcan Australia. Medicinal Cannabis operates in both the hemp and medicinal cannabis industries and has been one of the key drivers in providing value for the group. MedCan Australia produces a range of products including dried cannabis flowers, full extract oils, and cannabis capsules.
MedCan were also one of the first medicinal marijuana stocks to receive a production licence from the Office of Drug Control. They’ve continued their hunt for licences, now holding a Cultivation and Production Licence, a Manufacturing Licence and a Import & Export Licence.
Cann Global, as their name suggests, continue to dip their hands into a wide range of cannabis related niches. Including researching, educating, manufacturing, and more.
Cann Group – CAN
Cann Group was the first company in Australia to receive a licence to cultivate medicinal cannabis. They plan to develop extracts which will be provided to researchers and clinicians to study the therapeutic effects of cannabis.
Cann Group currently operates two cannabis cultivation facilities in Melbourne, already having completing 25 harvests. They plan to continue their expansion, with eyes set on a $130 million cannabis facility in Mildura – expecting it to produce around 50,000 kg of cannabis each year.
Cann Group has reached a significant milestone in early 2020. Announcing that they’re pleased to report that the first of its GMP manufactured product formulations, dried cannabis flower and cannabis oil from its Australian-grown cannabis, have completed initial shelf life stability testing and can now be released to the market to fill specific customer orders.
CannPal – CP1
CannPal is currently researching and planning to develop a range of cannabinoid medicines for therapeutic use to treat pets in a safe and ethical way.
Although the company is based in Australia, the local market for therapeutic animal products is quite small. As such, CannPal is focusing more on the European and US markets.
Layton Mills (MD) states no other animal therapeutics company in these regions are conducting clinical trials of a similar nature using cannabinoids from the cannabis plant.
CannPal continues to develope strategic relationships with some high level organisations in Australia, in particular, the CSIRO. CSIRO has granted CannPal an exclusive global licence to commercialise their patended MicroMAX microensapcsulation technology in the field of Animal Therapeutics.
Creso Pharma – CPH
Creso Pharma is one of the few ASX cannabis stocks to already have its hands in established markets overseas. iIn February 2019, they were granted a License To Cultivate at a 24,000 sqft cannabis facility in the world’s largest cannabis legal market – Canada. They aim to produce 4,000 kgs of cannabis per year to start off.
They were also one of the first to import medicinal cannabis in Australia, and one of the first to launch hemp and CBD nutraceutical products in Switzerland.
Like a few other cannabis stocks, Creso seeks to become “the world’s most trusted supplier of cannabis and hemp derived products”.
Creso has already showcased strong growth over the past year and leading into 2020. For 2020 Q1, the group’s revenue exceeded $1 million, up from just over $100k during 2019 Q1.
Elixinol Global – EXL
Elixinol Global has a number of subsidiaries it owns operating in various cannabis and hemp markets. Hemp Foods Austalia – one of Australia’s largest hemp food wholesalers and exporters. Elixinol Australia – was founded in 2014 to participate in the growing medicinal cannabis market. It’s still waiting for a cultivation and manufacturing licence.
There are big plans for Elixinol Australia should its licence be approved. The company plans to explore breeding, cultivation, extraction, manufacturing, formulation, clinical trials, education, and doctor outreach.
Elixinol announced more fund raising for their company in May 2020 as well as presenting a refined strategy during an investor presentation. With notes to focusing on their branded business model and digitally led consumer communications.
Impression Healthcare – IHL
Impression Healthcare has taken a forward stance on the Australian cannabis markets, planning to import and sell various cannabis products.
The deal has been struck with AXIM Biotechnologies, a US-based company who produce and manufacture a range of cannabis products. It gives Impression Healthcare exclusive rights to sell and distribute AXIM’s current, and future range of products in Australia and New Zealand.
However, Impression Healthcare is yet to obtain licences from the Office of Drug Control for this operation.
Impression Healthcare has been quite sparse in their announcements relating to their cannabis activites in Australian so far in 2020. The single announcement they have made was that they’re preparing for an obstructive sleep apnoea clinical trial to take place in the June quarter this year.
Medlab Clinical – MDC
As an already established ASX listed company with a wide variety of medicines available to patients on their website, MedLab has recently dived head first into their first CBD/THC medicines, called NanaBis and NanaBidial.
Based on a recent analysis of five case studies, MedLab is actively pursuing regulatory pathways with the Therapeutic Goods Administration and already has a planned framework in place that should take Nanabis to an approved drug.
Medlab recently completed and closed its depression trial being conducted at Queensland
University of Technology (QUT). The trial was closed early as a significant trendline had already been achieved. Pathology and Independent review expected in 3 months.
MGC Pharmaceuticals – MXC
MGC Pharmaceuticals currently manufactures a range of CBD & THC medicines for treating adverse conditions including epilepsy, inflammation, and cachexia. You can find their current pharmaceutical products here<.
In addition to their current products, MGC is also researching new ones, as well as establishing multiple cannabis cultivation facilities around the world to provide an effective and cost-friendly supply chain.
MGC Pharma is one of the few cannabis companies around the world conducting trials on Covid-19 patients and cannabis. The Trial, taking place at Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, is expected to conclude recruitment in September 2020 with results available October 2020. They have also increased their prescriptions numbers five fold since October 2019.
MMJ Group – MMJ
The MMJ Group is an Australia listed cannabis stock which primarily invests in other cannabis companies. These companies are located all over the world, with a few here in Australia as well, such as Cannabis Access Clinics.
Most of their portfolio lies in the medicinal cannabis industry. Invested companies include Harvest One, Cannabis Access, Weed Me, Bien, Embark Health, and many more.
Roots Sustainable – ROO
Roots currently has a number of readily-available commercial products and is also developing new technologies to improve the process of traditional growing systems.
These systems aim to increase yields, improve plant quality, provide significant cost and energy savings, and help protect against cold and heat stress.
In a recent study, Roots was able to increase cannabis yields by 60% to 283% in dried un-trimmed cannabis bud weight.
Although their stock price has taken a big hit over the past few years, Roots Sustainable continues to move forward with their plans. They’ve recently announced a collaboration with FinePro Consulting Ltd and their RZTO technology increasing yield of Okra by 78%. Both announcements can be read on their website.
RotoGro International – RGI
RotoGro develops and manufactures a range of growing equipment used for cannabis and other plants which increase yields and lowers operating costs. Their unique stackable growing system provides nine times the surface area (when stacked three high) for growing, compared to a traditional flat bed.
As well, RotoGro has recently wholly acquired the lawful Canadian cannabis company – Supra THC Services Inc. This purchase agreement includes a Dealer’s Licence issued by Health Canada. This licence allows the company to research, produce, sell, and distribute lawful cannabis products.
RotoGro continues to focus on their pending patents. In April 2020, they announced an expectation of their European patent to be granted on 22 April 2020.
StemCell United – SCU
StemCell United currently extract Dendrobium Officinale and Daemonorops Draco Blume – both high in demand for medical, health care, and beauty products. It plants to bring similar extract method to cannabis.
The company recently acquired a 51% share in Yunnan Hua Fang Industrial Hemp Limited (HFIF) which has an industrial hemp licence in China. StemCell’s CEO stated the acquisition “will facilitate StemCell’s expansion into the TCM (Traditional Chinese Medicine) cannabis beauty products whilst opening doors to China’s vast beauty industry market and distribute cosmetic cannabis product through a significantly expanded network”.
StemCell continues to remain mostly quite about its operations in the cannabis niche.
THC Global – THC
As one of Australia’s current leading ASX listed medicinal marijuana companies, THC Global is in a prime position to continue their expontential growth. They’ve already secured partners across four continents, priming them for their future international growth.
On top of their Australian plans to culative and produce cannabis, THC Gobal also operates a global hydroponics business – manufacturing and distributing equipment, materials, and nutrients.
The company already has two grow sites at the ready in Queensland and New South Sales – expecting annual productions to be in the tens of thousands of kilograms.
THC maintains its position as one of the strongest and largest listed cannabis companies in Australia. From their CEO – “We are committed to bringing lower costs and higher quality to Australian patients. Our complete control of cannabis biomass, manufacturing, supply, and support will help achieve this. We expect to supply at least an initial 6,000 patients using Canndeo medicinal cannabis on an ongoing basis commencing from Q2 2020. Further Australian patients and global exports will follow”.
Zelda Therapeutics – ZLD
Zelda Therapeutics is a bio-pharmaceutical company developing a range of cannabis medicines to treat illnesses such as insomnia, autism, cancer, and to reduce opioid use. Trials and clinical studies are currently being conducted with assistance from the University of Western Australia, the Complutense University in Spain, the Children’s Hospital of Philadelphia, and more organisations.
Zelda’s products are at various stages in the pipeline, with none ready for use as of March 2019.
Zelda has recently partnered with US-based Ilera Healthcare, providing Zelda with access to over 80,000 registered medicinal cannabis patients, and positioning them for rapid commercialisation of their future clincally-validated products.
Zelda Therapeutics continues to conduct trials testing potential medicines. One trial in particular, concerning the effectiveness of ZTL-101 (one of their drugs) in insomnia recently produced promising results. With the study showing statistically significant improvements in time spent asleep, time taken to return to sleep after waking, sleep quality, and feeling rested.
Why Invest In Cannabis Stocks?
In a report published in April 2018, Grand View Research estimated the global legal cannabis market to be worth nearly $150 billion by 2025. They even mention Australia among other countries such as Germany, USA, and Canada as regions expected to become leading markets in terms of sales. More recent studies and projections estimate the Australian cannabis industry to be worth $1.5 billion by 2024 should recreational cannabis be leglised nationally, like it has been in the ACT.
Australia has both a great political and environmental industry for producing some of the highest quality grade medicinal marijuana. We’ve got the equipment, the experts, the standards, and the know-how. Those companies with licences to export locally grown cannabis and cannabis medicines from the Office of Drug Control are going to benefit greatly in revenues and strategic partnerships.
On top of the massive overseas demand, there are plenty of Australian consuming cannabis each year – whether it be for medicinal use or recreationally. Statistics show 7 million Australians have used cannabis at least once in their lifetime, with 2 – 3 million consuming cannabis in the past 12 months.
In terms of the current medicinal cannabis market, cannabis medicines are already starting to increase dramatically, on top of the growing number of approvals by the Therapeutic Goods Administration for these medicines, we can expect to see exponential increases in revenues for those playing the field the right way.
If we expand our timeframe to include legal recreational cannabis in Australia, more figures from the Oceania Cannabis Report estimate the industry could be worth $12.3 billion by 2028, with nearly $9 billion of that coming from recreational users once it’s legalised (even if Bill Shorten says he won’t do it).
There’s no doubt about it – recreational cannabis is coming. The positive effects seen in Canada, and the US states which have legalised recreational use is overwhelming.
Above, you’ll find a list of all the major cannabis companies listed on the ASX. There are plenty of companies looking to leave a lasting legacy in the industry, and there will likely be many more to join them in the near future.